5 Hard-Hit Dow Stocks Have Monster Potential, Offer Great Dividends – 24/7 Wall St.


It’s hard to believe, but after a very positive double-digit year for stocks, there are only two months left in 2021. Now is the time when many investors will revise their portfolios and make changes for the last eight. weeks of the year and 2022. One thing’s for sure: The Federal Reserve will start cutting its $ 120 billion a month asset purchases later this month, cutting its asset purchases by $ 15 billion. obligations. While Fed Chairman Jay Powell has made his tapering intentions very clear, that doesn’t mean some additional volatility might not be part of the mix as we close the year.

It now makes sense to move from dynamic, memes stocks to more conservative large-cap stocks that pay dividends. We have selected Dow Jones Industrials in search of high yielding companies in sectors that appear to be benefiting from the continued reopening of the economy. We also looked for stocks that have traded lower this year and have offered some of the best entry points for some time.

While all are rated Buy in Top Wall Street Companies, it is important to remember that no analyst report should be used as the sole basis for any buy or sell decision.


This biotech giant remains a prominent stock for investors to buy and a safer way to profit from the massive potential growth of biosimilars. Amgen Inc. (NASDAQ: AMGN) discovers, develops, manufactures, and supplies human therapeutics around the world. He focuses on inflammation, oncology / hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

The company’s products include the following:

  • Enbrel to treat plaque psoriasis, rheumatoid arthritis and psoriatic arthritis
  • Neulasta reduces risk of infection due to low white blood cell count in cancer patients
  • Prolia to treat postmenopausal women with osteoporosis
  • Xgeva for the prevention of skeletal-related events
  • Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s disease
  • Aranesp to treat lower than normal red blood cell count and anemia
  • Kyprolis to treat patients with relapsed or refractory multiple myeloma
  • Repatha, which reduces the risk of myocardial infarction, stroke and coronary revascularization

Amgen also markets Nplate, Vectibix, Mvasi, Parsabiv, Epogen, Kanjinti, Blincyto, Aimovig, Evenity, Amgevitatm, Sensipar / Mimpara, Neupogen, Imlygic, Corlanor and Avsola. The company’s five key marketed products are among the world’s best-selling pharmaceuticals, with the company forecasting collective revenues of more than $ 25 billion in 2021.

Shareholders receive a dividend of 3.28%. BMO Capital Markets has a target price of $ 301 on Wall Street for Amgen stock. The consensus target is only $ 249.38 and Thursday’s final trade came in at $ 214.93.


Previous Alan Wilson secretly recorded how victim was shot in the 'forehead', court said
Next Source Audio C4 Synth Reviews

No Comment

Leave a reply

Your email address will not be published.